244 related articles for article (PubMed ID: 3960398)
21. Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson's disease.
Bennett JP; Wooten GF
Ann Neurol; 1986 Apr; 19(4):378-83. PubMed ID: 3707090
[TBL] [Abstract][Full Text] [Related]
22. N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain.
Xu SX; Hatada Y; Black LE; Creese I; Sibley DR
J Pharmacol Exp Ther; 1991 May; 257(2):608-15. PubMed ID: 1674530
[TBL] [Abstract][Full Text] [Related]
23. In vivo partial inactivation of dopamine D1 receptors induces hypersensitivity of cortical dopamine-sensitive adenylate cyclase: permissive role of alpha 1-adrenergic receptors.
Trovero F; Hervé D; Blanc G; Glowinski J; Tassin JP
J Neurochem; 1992 Jul; 59(1):331-7. PubMed ID: 1351927
[TBL] [Abstract][Full Text] [Related]
24. Dopamine receptor occupancy in vivo: measurement using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ).
Saller CF; Kreamer LD; Adamovage LA; Salama AI
Life Sci; 1989; 45(10):917-29. PubMed ID: 2529407
[TBL] [Abstract][Full Text] [Related]
25. Age-dependent differences in the rate of recovery of striatal dopamine D1 and D2 receptors after inactivation with EEDQ.
Crawford CA; Rowlett JK; McDougall SA; Bardo MT
Eur J Pharmacol; 1994 Feb; 252(2):225-31. PubMed ID: 8157063
[TBL] [Abstract][Full Text] [Related]
26. Unilateral inactivation of dopamine receptors after intrastriatal injection of N-ethoxy-carbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ): a novel rotational model to investigate dopamine receptor interactions.
Giorgi O; Biggio G
Pharmacol Biochem Behav; 1990 Apr; 35(4):877-84. PubMed ID: 1971721
[TBL] [Abstract][Full Text] [Related]
27. Effect of chronic estradiol treatment on brain dopamine receptor reappearance after irreversible blockade: an autoradiographic study.
Morissette M; Lévesque D; Di Paolo T
Mol Pharmacol; 1992 Sep; 42(3):480-8. PubMed ID: 1357544
[TBL] [Abstract][Full Text] [Related]
28. Cation regulation differentiates specific binding of [3H]sulpiride and [3H]spiperone to rat striatal preparations.
Theodorou AE; Hall MD; Jenner P; Marsden CD
J Pharm Pharmacol; 1980 Jun; 32(6):441-4. PubMed ID: 6106685
[No Abstract] [Full Text] [Related]
29. Regional displacement by sulpiride of [3H]spiperone binding in vivo. Biochemical and behavioural evidence for a preferential action of limbic and nigral dopamine receptors.
Köhler C; Ogren SO; Haglund L; Angeby T
Neurosci Lett; 1979 Jun; 13(1):51-6. PubMed ID: 572522
[TBL] [Abstract][Full Text] [Related]
30. Effect of aging on striatal dopamine receptor subtype recovery following N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline blockade and relation to motor function in Wistar rats.
Henry JM; Joseph JA; Kochman K; Roth GS
Brain Res; 1987 Aug; 418(2):334-42. PubMed ID: 2960421
[TBL] [Abstract][Full Text] [Related]
31. Selective and stereospecific interactions of R-SK & F 38393 with [3H]piflutixol but not [3H]spiperone binding to striatal D1 and D2 dopamine receptors: comparisons with SCH 23390.
O'Boyle KM; Waddington JL
Eur J Pharmacol; 1984 Mar; 98(3-4):433-6. PubMed ID: 6144559
[TBL] [Abstract][Full Text] [Related]
32. Dopaminergic component of [3H]spiroperidol binding in the rat anterior cerebral cortex.
Marchais D; Tassin JP; Bockaert J
Brain Res; 1980 Feb; 183(1):235-40. PubMed ID: 7357406
[No Abstract] [Full Text] [Related]
33. Day/night differences in D1 but not D2 DA receptor protection from EEDQ denaturation in rats treated with continuous cocaine.
Burger LY; Martin-Iverson MT
Synapse; 1993 Jan; 13(1):20-9. PubMed ID: 8093985
[TBL] [Abstract][Full Text] [Related]
34. Effect of chronic sulpiride on striatal spiperone binding.
Bannet J; Gillis S; Ebstein RP; Belmaker RH
Int Pharmacopsychiatry; 1980; 15(6):334-7. PubMed ID: 7298264
[TBL] [Abstract][Full Text] [Related]
35. High affinity dopamine D2 receptor radioligands. 2. [125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors.
Kessler RM; Ansari MS; Schmidt DE; de Paulis T; Clanton JA; Innis R; al-Tikriti M; Manning RG; Gillespie D
Life Sci; 1991; 49(8):617-28. PubMed ID: 1830917
[TBL] [Abstract][Full Text] [Related]
36. A comparison of the selectivities of SCH 23390 with BW737C89 for D1, D2 and 5-HT2 binding sites both in vitro and in vivo.
Riddall DR
Eur J Pharmacol; 1992 Jan; 210(3):279-84. PubMed ID: 1351844
[TBL] [Abstract][Full Text] [Related]
37. Differential recovery rates of rat D2 dopamine receptors as a function of aging and chronic reserpine treatment following irreversible modification: a key to receptor regulatory mechanisms.
Norman AB; Battaglia G; Creese I
J Neurosci; 1987 May; 7(5):1484-91. PubMed ID: 2952771
[TBL] [Abstract][Full Text] [Related]
38. Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors.
Hess EJ; Norman AB; Creese I
J Neurosci; 1988 Jul; 8(7):2361-70. PubMed ID: 2907912
[TBL] [Abstract][Full Text] [Related]
39. Quantification of in vivo spiperone binding in the rat striatum after lesions produced by kainate or decortication.
Van der Werf JF; Van het Schip F; Sebens JB; Korf J
Eur J Pharmacol; 1984 Jul; 102(3-4):387-99. PubMed ID: 6436037
[TBL] [Abstract][Full Text] [Related]
40. Chronic haloperidol affects striatal D2-dopamine receptor reappearance after irreversible receptor blockade.
Pich EM; Benfenati F; Farabegoli C; Fuxe K; Meller E; Aronsson M; Goldstein M; Agnati LF
Brain Res; 1987 Dec; 435(1-2):147-52. PubMed ID: 2962698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
